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Abstract 
Hepatitis C virus (HCV) infects 3% of world population being responsible for nearly half a million deaths annually 
urging the need for a prophylactic vaccine. Retrovirus like particles are commonly used scaffolds for antigens pres-
entation being the core of diverse vaccine candidates. The immunogenicity of host proteins naturally incorporated 
in retrovirus was hypothesized to impact the performance of retrovirus based vaccines. In this work, the capacity of 
engineered retrovirus like particles devoided of host protein CD81 to display HCV envelope antigens was compared 
to non-engineered particles. A persistent inability of CD81 negative VLPs to incorporate HCV E2 protein as a result 
from the inefficient transport of HCV E2 to the plasma membrane, was observed. This work enabled the identifica-
tion of a CD81-mediated transport of HCV E2 while stressing the importance of host proteins for the development of 
recombinant vaccines.
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Introduction
With no licensed prophylactic vaccine, Hepatitis C virus 
(HCV) is considered one of the most important human 
pathogens of the XXI century, infecting approximately 
80 million people worldwide (Baumert et al. 2014; Gower 
et al. 2014). The high genetic diversity of HCV genotypes, 
the extended capacity of HCV to circumvent immune 
defenses and the absence of suitable animal models to 
evaluate vaccine efficacy are major challenges for HCV 
vaccine development (Bellier and Klatzmann 2013). 
Additionally, the risk of an asymptomatic HCV infection 
associated to vaccine reversion limits the use of classical 
inactivated and live-attenuated vaccine candidates.
As a result, HCV vaccine candidates undergoing pre-
clinical and clinical evaluation use non-conventional 
antigens such as vectored vaccines, recombinant pro-
tein cocktails and virus-like particles (VLPs) (Garrone 
et al. 2011; Huret et al. 2013). The latter have shown to 
be potent vaccine antigens as a result from their par-
ticulate nature even in the absence of adjuvants (Bellier 
et  al. 2006, 2009; Gogesch et  al. 2018). Virus-like par-
ticles based in Murine Leukemia virus (MLV) are the 
core of diverse vaccine candidates against pathogens 
such as Cytomegalovirus, West Nile fever virus, Hepa-
titis C virus and human immunodeficiency virus due to 
their capacity to incorporate high amounts of foreign 
membrane proteins (Bellier et  al. 2006, 2009; Desjar-
dins et  al. 2009; Kirchmeier et  al. 2014; Pitoiset et  al. 
2017). Murine Leukemia virus acquires its lipid enve-
lope by extracting a fragment of the plasma membrane 
during budding stage which results in the incorporation 
of host membrane proteins in fully assembled particles 
(Segura et al. 2008; Soares et al. 2016). We have previ-
ously shown that host proteins incorporated in MLV-
based VLPs, or retroVLPs, such as the tetraspanins 
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CD81, CD63 and CD9, trigger the production of anti-
bodies in mice thus conferring retroVLPs their basal 
immunogenity (Soares et al. 2016).
Similar to retrovirus, host proteins are known to 
associate with HCV virions (Lussignol et al. 2016). Even 
though the immunogenic profile of these host proteins 
is unknown, chronic HCV infections often result in the 
production of autoreactive antibodies (Roughan et  al. 
2012). Here we hypothesize the use of engineered ret-
roVLPs with reduced CD81-specific immunogenicity to 
study the role of host proteins in HCV immunity and to 
support the development of engineered HCV vaccine 
candidates.
In this work CD81 positive and CD81 negative cells 
were used to produce retroVLPs pseudotyped with 
HCV envelope proteins. An inefficient transport of 
HCV E2 to the plasma membrane of CD81 silenced 
cells however hampered HCV pseudotyping of retro-
VLPs in these cells. The inefficient transport of HCV E2 
was further confirmed in cells producing HCV-like par-
ticles. Contrasting with the prevalent hypothesis argu-
ing for an inefficient retention of viral proteins in the 
endoplasmic reticulum (ER) (Bartosch et  al. 2003; Op 
De Beeck et al. 2004) our results suggest the existence 
of a CD81-mediated transport of HCV E2 to the plasma 
membrane. Our results also show that the transport of 
HCV E1 is independent from HCV E2 and CD81 thus 
contributing for the development of E1-only vaccine 
candidates.
Materials and methods
Cell lines and culture media
293rVLP and 293rVLP-shCD81 cell lines derive from 
HEK 293 (ATCC CRL-1573) by stable expression of 
MLV gag-pro-pol gene for continuous production of 
recombinant retrovirus products (Rodrigues et al. 2011). 
293rVLP-HCVpp and 293rVLP-HCVpp shCD81 (BEE) 
cells derived from the previous cells by stable transfec-
tion of pEPX145-71 plasmid expressing HCV E1 and 
E2 genes (Garrone et  al. 2011) and pMonoZeoMCS, a 
plasmid containing the zeocin resistance gene in a ratio 
1:20 (m/m), using 1 µg P.E.I. to 1.5 µg of DNA. 293rVLP-
HCVpp shCD81 (AEE) cells derive from 293rVLP-
HCVpp upon silencing endogenous CD81 expression. To 
establish HCV-LP producer cells, HuH-7 (JCRB 0403) 
and HEK 293 (ATCC CRL-1573) were used. All cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Carlsbad, CA, USA) supplemented 
with 10% (v/v) fetal bovine serum (FBS) (Gibco) at 37 °C 
inside an incubator with a humidified atmosphere of 5% 
 CO2 in air. A summary table with all cell lines used and 
developed is available as Additional file 1: Table S1.
Cell transduction and selection
For the establishment of de novo CD81 silenced cell 
populations 293rVLP-HCVpp, 293-HCVCore-NS2 and 
HuH7-HCVCore-NS2 cells were seeded in six-well plates 
at 5 × 104  cells/cm2; 24  h later, culture medium was 
replaced by 600  µL of lentiviral supernatant containing 
shRNA#10, (Rodrigues et al. 2011) targeting CD81 sup-
plemented with 8 mg/mL of Polybrene (Sigma-Aldrich). 
After 4 h incubation at 37 °C, 1.5 mL of DMEM 10% FBS 
(v/v) was added. 48 h post-infection, cells were expanded 
and cultured for 21  days in DMEM containing puro-
mycin (1.5  mg/mL). For further enhancement of CD81 
down-regulation, initial shCD81#10 cell populations 
were subsequently infected with shCD81 #9 and #12, as 
described previously (Rodrigues et al. 2011), followed by 
14 days selection with 3 mg/mL puromycin, establishing 
the final shCD81 cell population. The development of 
293-HCVCore-NS2, HuH-7-HCVCore-NS2 and correspond-
ing shCD81 derived cells is summarized in Additional 
file 1: Figures S4 and S5 schematic representations.
Western Blotting
Cell lysates were prepared by adding 100  µL of M-PER 
extraction buffer (Thermo Scientific, Waltham, MA, 
USA) per 1 × 106 cells. The total protein concentration 
in cell lysates or purified virus samples was determined 
using Pierce™ BCA Protein Assay Kit (Thermo Scientific). 
15  µg of protein extracts or purified virus like particles 
were separated in a 4–12% (w/v) acrylamide NuPAGE 
gradient pre-cast gel (LifeTechnologies). Samples were 
resolved for 40  min at a constant voltage of 180  V and 
transferred into a PVDF membrane (Merck, Billerica, 
Massachusetts, EUA) using a Trans-Blot® Turbo™ Trans-
fer System (BioRad, California, USA). After transferring, 
PVDF membranes were blocked with 4% (w/v) skimmed 
milk (Merck) and incubated with the respective primary 
antibody: rabbit anti-CD81 (Sigma-Aldrich), mouse anti-
β-Tubulin antibody (SantaCruz, CA, USA), mouse anti-
HCV E1 (Acris Antibodies, Herford, Germany), mouse 
anti-HCV E2 (Austral Biologicals), mouse anti-HCV 
Core (SantaCruz) or the anti-MLV p30 monoclonal anti-
body produced by the hybridoma R187 (ATCC). Detec-
tion was performed with the corresponding anti-mouse 
or anti-rabbit secondary antibody conjugated to Horse-
radish peroxidase and developed using the ECL Detec-
tion Reagent (GE Healthcare, Chicago, IL USA).
Flow cytometry
To determine the presence of CD81 and HCV E2 on the 
cell surface 100 µL of a 1 × 106 cells/mL suspension were 
incubated with rabbit anti-CD81 (Sigma-Aldrich) and 
anti-HCV E2 (Austral Biologicals) monoclonal antibodies 
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for 1 h, shaking at 4 °C. After extensive washing with PBS 
2% (v/v) FBS, cells were incubated with Goat anti-Rabbit 
A594 (Thermo Scientific) and Goat anti-mouse A488 
(Thermo Scientific) conjugated antibodies for an addi-
tional hour at 4 °C. At the end, cells were washed 3× with 
PBS 2% (v/v) FBS and the percentage of fluorescence cells 
was determined by flow cytometry using CYFlow space 
flow cytometer (Partec, Münster, Germany). Data acqui-
sition was performed with FlowMax (Partec) software 
and data analysis with FlowJo v10 (FlowJo, LLC, Ashland, 
Ore USA).
Results
CD81 silencing impairs HCV E2 but not HCV E1 transport 
to the plasma membrane
To study the influence of viral CD81 in HCV immunity 
and vaccine performance, endogenous CD81 expression 
was silenced in retroVLPs producing cells before and 
after inducing the heterologous expression of HCV enve-
lope proteins (Fig.  1; Additional file  1: Figures  S1, S2). 
These cells were named 293rVLP-HCVpp shCD81 (AEE) 
and 293rVLP-HCVpp shCD81 (BEE) cells, as a reference 
to CD81 silencing occurring After Envelope Expression 
or Before Envelope Expression, respectively. HCVpp 
refers to HCV pseudoparticles which are retroviral par-
ticles pseudotyped with HCV envelope proteins. The 
expression of CD81, HCV envelope proteins and MLV 
structural protein p30 was evaluated in all engineered 
cell lines and derived particles. As shown in Fig. 2a and 
Additional file 1: Figure S3, the cellular expression of all 
viral proteins in CD81-positive and in CD81-negative 
cells is similar. On the other hand the analysis of envelope 
proteins incorporated on viral particles (Fig. 2b) revealed 
a reduced incorporation of HCV E2 in HCVpp produced 
by CD81-silenced cell lines while HCV E1 incorporation 
levels were maintained. To evaluate the transport of HCV 
E2 to retroVLPs budding site at the plasma membrane, 
the display of HCV E2 on the cell surface was determined 
by flow cytometry. As shown in Fig. 2c, HCV E2 is con-
sistently lower in CD81-silenced cells in comparison to 
non-silenced cells, thus explaining the lower incorpora-
tion of HCV E2 on budding HCVpp.
CD81‑dependent transport of HCV E2 in HCV‑core 
expressing cells
To investigate the existence of a CD81-dependent trans-
port of HCV E2 in cells producing HCV particles, endog-
enous CD81 expression was silenced in HEK293 and 
HuH-7 cells expressing HCV viral proteins (Core, E1, 
E2, p7 and NS2) (Fig. 3a and Additional file 1: Figure S4). 
HCV proteins were overexpressed in three independ-
ent open reading frames originating  HEK293Core-NS2 and 
Fig. 1 Schematic representation of cell line development. 293rVLP cells producing non pseudotyped retrovirus like particles (Null VLPs) were 
transfected with HCV envelope E1 (green) and E2 (brown) proteins coding plasmid and produced HCV pseudoparticles (HCVpp), afterwards these 
cells were silenced for endogenous CD81 generating 293rVLP-HCVpp shCD81 (AEE—After Envelope Expression) (upper panel). In parallel, 293rVLP 
were silenced for endogenous CD81 expression to produce non-pseudotyped retrovirus like particles deprived from CD81, these cells were then 
transfected with a plasmid coding HCV envelope proteins generating 293rVLP-HCVpp shCD81 (BEE—Before Envelope Expression) (lower panel)
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HuH-7Core-NS2 cells (Fig. 3a and Additional file 1: Figure 
S4). The silencing of endogenous CD81 expression after 
the stable expression of HCV proteins (Fig. 3a and Addi-
tional file 1: Figure S4) did not alter the cellular expres-
sion levels of viral proteins (Fig.  3b). Nonetheless, a 
reduction in cell surface exposed HCV E2 is observed in 
both  HEK293Core-NS2 shCD81 and HuH-7Core-NS2 shCD81 
(Fig.  3c, d) similar to HCVpp producing cells. Further-
more, CD81 silencing did not affect the intracellular 
assembly of HCV-LP occurring at the endoplasmic retic-
ulum (Additional file 1: Figure S5).
Discussion
The emergence of virus-like particles (VLPs) as vaccine 
scaffolds enabled the development of vaccine candidates 
for conditions which other technologies have failed. MLV 
based particles were shown to efficiently incorporate 
HCV envelope antigens from different genotypes and 
to generate antibodies able to cross-neutralize all tested 
genotypes thus generating protective immunity (Garrone 
et al. 2011; Huret et al. 2013; Urbanowicz et al. 2015).
We have previously shown that host proteins present 
in MLV particles, such as CD81, are responsible for ret-
roVLPs basal immunogenity (Soares et  al. 2016). Since 
CD81 is a crucial host-factor for Hepatitis C virus, the 
impact of CD81 incorporation and the generation of anti-
CD81 antibodies in the performance of retroVLPs based 
vaccines was questioned.
In 2004, Masciopinto et al. (2004) showed that hCD81 
expression in CHO-cells promoted the transport of HCV 
envelope proteins to the plasma membrane and conse-
quently their incorporation in exosomes. Regardless, the 
idea of a non-regulated process in which a small fraction 
of viral proteins escaping the ER retention machinery are 
incorporated in the plasma membrane prevails as the 
mechanism responsible for the incorporation of HCV 
envelope proteins in chimeric viral particles (Bartosch 
et  al. 2003; Op De Beeck et  al. 2004). Here we validate 
the transport of HCV E2 envelope protein to the plasma 
Fig. 2 Cellular expression of and incorporation of HCV envelope proteins in chimeric HCVpp. a Cellular expression of MLV p30, CD81, HCV E1 and 
HCV E2 determined by western blotting in 293rVLP, 293rVLP-HCVpp, 293rVLP-HCVpp (AEE), 293rVLP-shCD81 cells and 293rVLP-HCVpp-shCD81 
(BEE); b incorporation of CD81, HCV E1 and HCV E2 membrane proteins in null retrovirus particles or HCVpp produced in 293rVLP, 293rVLP-HCVpp, 
293rVLP-HCVpp (AEE), 293rVLP-shCD81 cells and 293rVLP-HCVpp (BEE) cells determined by western blotting of purified particles; c surface displayed 
CD81 and HCV E2 proteins 293rVLP, 293rVLP-HCVpp, 293rVLP-HCVpp (AEE), 293rVLP-shCD81 cells and 293rVLP-HCVpp (BEE) cells determined by 
flow cytometry
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membrane as a regulated process dependent from cellu-
lar CD81 expression.
To further validate our observations, CD81 negative 
HCVpp were generated independently and produced in 
a clonal cell line or in a heterogeneous cell population. To 
enable a direct comparison between cell lines generated 
independently, single cell clones with similar expression 
of viral proteins were isolated and named 293rVLP-
HCVpp and 293rVLP-HCVpp shCD81 (BEE) (Additional 
file  1: Figures  S1 and S2). To minimize the potential 
amplification of unwanted characteristic underrepre-
sented in the initial cell population during clonal selec-
tion, CD81 was de novo silenced in 293rVLP-HCVpp 
generating 293rVLP-HCVpp shCD81 (AEE) which was 
maintained as an heterogeneous cell population. A sche-
matic representation of cell line development is shown in 
Fig. 1 and summarized in Additional file 1: Table S1.
The evaluation of protein expression levels in all gen-
erated cell lines indicates similar expression of HCV 
envelope proteins, similar silencing of CD81 and main-
tenance of MLV p30 expression levels (Fig. 2a). Notwith-
standing similar protein expression, the levels of HCV 
E2 envelope protein incorporated by secreted viral parti-
cles and exposed at cell surface was consistently lower in 
CD81-silenced cells suggesting an inefficient transport of 
HCV E2 to the plasma membrane (Fig. 2b, c). The coher-
ent reduction of surface exposed HCV E2 in HEK293 
and HuH-7 cells producing HCV-LP after CD81 silenc-
ing further validates the existence of an in cis interaction 
between intracellular CD81 and HCV E2 responsible for 
HCV E2 transport to the membrane.
In contrast, CD81 silencing had no impact in the incor-
poration of HCV E1 on HCVpp suggesting independ-
ent transport mechanisms. The independent transport 
of HCV E1 grants the possibility to generate viral parti-
cles pseudotyped exclusively with HCV E1 using natural 
HCV sequences through cell line engineering. A chimeric 
HCV E1 protein enabling E1-only pseudotyping of retro-
VLPs, was shown to enhancing the protective potential 
of a vaccine candidate by increase the prevalence of rare 
anti-HCV E1 antibodies when administered in combina-
tion with fully pseudotyped particles in a prime-boost 
vaccination strategy (Garrone et  al. 2011; Huret et  al. 
2013).
Fig. 3 Validation of CD81-dependent transport of HCV E2 in HCV core expressing cells. a Schematic representation of the expression 
plasmids containing lentiviral vectors transgene sequences inducing the cellular expression of HCV Core, E1E2 and p7NS2 ORFs; b cellular 
expression of MLV p30, CD81, HCV E1 and HCV E2 determined by western blotting in HEK293, HEK293-HCVCore-NS2, HEK293-HCVCore-NS2 shCD81, 
HuH-7, HuH7-HCVCore-NS2 and HuH7-HCVCore-NS2 shCD81. c Surface displayed CD81 and HCV E2 proteins in (c) HEK293, HEK293-HCVCore-NS2, 
HEK293-HCVCore-NS2 shCD81 and d HuH-7, HuH7-HCVCore-NS2 and HuH7-HCVCore-NS2 shCD81
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Overall, this study provides evidences that HCV enve-
lope protein E2 transport is regulated by its intracellular 
association with cellular CD81. The validation of a CD81-
regulated transport of HCV E2 to the plasma membrane 
can further contribute to elucidate understudied aspects 
of HCV biology such as the biogenesis of infectious 
HCV-genome containing exosomes present in patients’ 
serum. In addition, this work grants the possibility to 
develop HCV E1-only particles using non-engineered 
viral envelopes and highlights the importance of cellular 
host proteins for the production of functional vaccine 
candidates.
Additional file
Additional file 1.  Additional Materials and Methods, Results, Tables and 
References.
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